iCAD, Inc. (ICAD)
- Previous Close
3.7600 - Open
3.7000 - Bid 3.6500 x 100
- Ask 3.7100 x 100
- Day's Range
3.6750 - 3.7700 - 52 Week Range
1.1800 - 4.0100 - Volume
154,697 - Avg. Volume
815,633 - Market Cap (intraday)
100.317M - Beta (5Y Monthly) 1.39
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1900 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.75
iCAD, Inc. provides AI-powered cancer detection solutions in the United States. The company's ProFound Breast Health Suite offers solutions for?breast?cancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and cardiovascular risk assessment related to elevated levels of breast arterial calcifications; and enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Detection solutions include advanced artificial intelligence and image analysis workflow solutions to identifying pathologies and pinpointing prevalent cancers earlier; and a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging, and computed tomography. In addition, the company suite offers solutions for cancer detection, density assessment, and personalized risk evaluation based on a 2D or 3D mammogram's collection of images. Additionally, its density assessment standardizes and simplifies breast density reporting by algorithmically examining a woman's breast anatomy from the mammogram image. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
www.icadmed.comRecent News: ICAD
View MorePerformance Overview: ICAD
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ICAD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ICAD
View MoreValuation Measures
Market Cap
100.32M
Enterprise Value
80.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.98
Price/Book (mrq)
3.26
Enterprise Value/Revenue
4.13
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.77%
Return on Assets (ttm)
-9.03%
Return on Equity (ttm)
-16.53%
Revenue (ttm)
19.53M
Net Income Avi to Common (ttm)
-5.23M
Diluted EPS (ttm)
-0.1900
Balance Sheet and Cash Flow
Total Cash (mrq)
20.03M
Total Debt/Equity (mrq)
1.00%
Levered Free Cash Flow (ttm)
-90k